pngvl4a-sig/e7
Biologicalexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT00121173)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pngvl4a-sig/e7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06508138 | Phase 1 | Oct 18, 2023 | Johns Hopkins University, National Cancer Institute (NCI), PapiVax Biotech, Inc. |
| NCT00788164 | Phase 1 | Nov 1, 2008 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00121173 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2003 | Johns Hopkins University, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 3 | 3 | 2 | 2003 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2003 |
| PapiVax Biotech, Inc. | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1